Member Info for Wiggly

The major risk was always widespread activation due to low lying FAPa. DE proved to a degree that this risk had been overcome.

We have had rises before but nothing that has been as sustained as this.

Perhaps AS decided to under promise / over deliver and will release PK data during Q1?

Well its now 35% and 75p!

Has to be some substance to this rise!!

I wonder... confirmation of efficacy after the 50% DE? Results would be visible by now

.

It is starting to feel like the market does not need any more clues...

1. 3996 Selection (as per Neil Bell, 3996 would be selected following receipt of very critical data confirming the Pre|cision mechanism of action)

2. DE by 50%

3. Addition of Christina Coughlin to drive Pre|cision to next level

4. Avacta + BACH et al to present AVA6k 'pre-clinical' data while 8 months deep into clinical trial

'Motoring extremely well with remarkably consistent data.. '

What does Linden have to do with AVA6k?

What does Linden have to do with the pre clinical AVA6k....?

Would be pointless to present the pre clinical data if the clinical data was not meeting the objective.

Can you imagine for a moment our CMO Fiona McLaughlin presenting pre clinical data while in knowledge that the clinical data was a dud? AS might blag it but the CMO would not stand for those orders.

Lots of clues now and can still buy in the 50s

Bein, why do you think we didn't release the data?

And after 7 months of trial data, including DE, it's still being described by a NED, publically via Twitter, as promising the disruptive...

To repeat...it's early days but positive signs are there and I don't think we could have hoped for better at this stage, 7 months in

I'd expect her to have ethics and integrity, therefore (assuming she received inside info related to Precision - which I am sure she did) I would not expect her to say that the preCISION platform holds great promise for patients and potentially disruptive in the oncology field if the data she viewed was not positive...

Any point from now we could wake up to a 7am blockbuster / company making RNS...

Highly possible news could relate to:

-Precision license deal
-Precision data release
-LG chem transformational progress
-Wild card news

Traders beware.

Under a non disclosure agreement I'm sure they did share key data with her. I'm sure they shared that they were highly confident based on current safety profile and confirmation of the mechanism of activation, inclusive of all available data. She is here to partly drive precision and therefore would not have undertaken this role if data indicated poor performance.

Still early days but I don't think we could have wished for more at this stage. Can't wait for disclosure of the data

Simon,

To repharse your comment...

Surely a statement such as the one posted could not have been made after reviewing poor Ava6k data.

..

Meduflow has now been validated against omicron?

What does this mean?

They have inside information regarding the performance of av6k so of course they cannot buy!!